TY - JOUR
T1 - Enhancement of dissolution rate of rofecoxib using solid dispersions with urea
AU - Liu, Chengsheng
AU - Desai, Kashappa Goud H.
AU - Liu, Chenguang
AU - Park, Hyun J.
PY - 2004/12
Y1 - 2004/12
N2 - The aim of this study was to enhance the dissolution rate of rofecoxib using solid dispersions (SDs) with urea. In preliminary studies, the solubility behavior of rofecoxib in the presence of polyethylene glycol (PEG)-4000, polyvinylpyrrolidone (PVP) K30, mannitol, and urea in water was obtained at 37°C to choose an effective carrier for preparing its SDs. A systematic increase in the solubility behavior of rofecoxib was observed with increasing concentrations of these carriers in water except mannitol. The Gibbs free energy (ΔGtro) values were negative indicating the spontaneous nature of rofecoxib solubilization, and it decreased with increases in concentration, demonstrating that the reaction became more favorable as the concentration of these carriers increased. Since, urea exhibited higher solubilizing power than the other carriers, SDs of rofecoxib with urea were prepared at 1:1, 1:2, 1:5, and 1:10 (rofecoxib:urea) ratios by the fusion method. Evaluation of the properties of the SDs was performed using dissolution studies, fourier-transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), X-Ray diffraction (XRD), and scanning electron microscopy (SEM). The dissolution rate of rofecoxib was enhanced rapid by its SDs with urea and increased with increasing concentrations of urea in SDs. The mean dissolution time (MDT) of rofecoxib decreased after preparation of SDs and physical mixtures with urea. FTIR spectroscopic studies showed the stability of rofecoxib and the absence of a well-defined rofecoxib-urea interaction. DSC and XRD studies confirmed the amorphous state of rofecoxib in SDs of rofecoxib with urea. SEM pictures showed the formation of effective SDs of rofecoxib with urea since well-defined changes in the surface nature of rofecoxib, SDs, and physical mixture were observed.
AB - The aim of this study was to enhance the dissolution rate of rofecoxib using solid dispersions (SDs) with urea. In preliminary studies, the solubility behavior of rofecoxib in the presence of polyethylene glycol (PEG)-4000, polyvinylpyrrolidone (PVP) K30, mannitol, and urea in water was obtained at 37°C to choose an effective carrier for preparing its SDs. A systematic increase in the solubility behavior of rofecoxib was observed with increasing concentrations of these carriers in water except mannitol. The Gibbs free energy (ΔGtro) values were negative indicating the spontaneous nature of rofecoxib solubilization, and it decreased with increases in concentration, demonstrating that the reaction became more favorable as the concentration of these carriers increased. Since, urea exhibited higher solubilizing power than the other carriers, SDs of rofecoxib with urea were prepared at 1:1, 1:2, 1:5, and 1:10 (rofecoxib:urea) ratios by the fusion method. Evaluation of the properties of the SDs was performed using dissolution studies, fourier-transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), X-Ray diffraction (XRD), and scanning electron microscopy (SEM). The dissolution rate of rofecoxib was enhanced rapid by its SDs with urea and increased with increasing concentrations of urea in SDs. The mean dissolution time (MDT) of rofecoxib decreased after preparation of SDs and physical mixtures with urea. FTIR spectroscopic studies showed the stability of rofecoxib and the absence of a well-defined rofecoxib-urea interaction. DSC and XRD studies confirmed the amorphous state of rofecoxib in SDs of rofecoxib with urea. SEM pictures showed the formation of effective SDs of rofecoxib with urea since well-defined changes in the surface nature of rofecoxib, SDs, and physical mixture were observed.
KW - Dissolution rate
KW - MDT
KW - Rofecoxib
KW - Solid dispersion
KW - Solubility
KW - Urea
UR - http://www.scopus.com/inward/record.url?scp=16344362340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16344362340&partnerID=8YFLogxK
U2 - 10.1002/ddr.10412
DO - 10.1002/ddr.10412
M3 - Article
AN - SCOPUS:16344362340
SN - 0272-4391
VL - 63
SP - 181
EP - 189
JO - Drug Development Research
JF - Drug Development Research
IS - 4
ER -